Ignite Creation Date:
2024-05-06 @ 5:46 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05420545
Status:
RECRUITING
Last Update Posted:
2023-08-18
First Post:
2022-06-12
Brief Title:
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive AdvancedMetastatic Solid Tumors
Sponsor:
Chongqing Precision Biotech Co Ltd
Organization:
Chongqing Precision Biotech Co Ltd
Study Overview
Official Title:
A Phase I Clinical Study of CD70-targeting CAR-T Therapy in the Treatment of CD70-positive AdvancedMetastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advancedmetastatic solid tumors and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose
Detailed Description:
This is a single-center double-arm open-label study The study plans to set up 2 groupsIntravenous infusion group have 4 dose groups adopting a dose-escalating 33 design and plan to recruit about 12 subjects with CD70-positive advancedmetastatic solid tumorsIntraperitoneal injection group have 4 dose groups adopting a dose-escalating 33 design and plan to recruit about 12 subjects with CD70-positive advancedmetastatic solid tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None